If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Tirzepatide
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
SURPASS-2 compared tirzepatide with once-weekly semaglutide 1 mg, the highest approved dose of semaglutide available at the time.1,2
Lilly has not conducted and are not currently conducting clinical studies comparing tirzepatide with once-weekly semaglutide 2 mg.2
1A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2). ClinicalTrials.gov identifier: NCT03987919. Updated March 11, 2021. Accessed March 23, 2021. https://clinicaltrials.gov/ct2/show/NCT03987919
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Lilly = Eli Lilly and Company
Date of Last Review: March 23, 2021
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST